News | December 15, 2025
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
The event will be attended by 35,000+ industry professionals
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
This certification validates the plant’s robust capabilities in manufacturing a wide range of sterile dosage forms
Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats
Akums invested Rs. 272 crore in capital expenditure during FY25
Akums and TNAU will collaborate to strengthen research through shared expertise and innovative agricultural solutions, to foster innovation in formulation development
Subscribe To Our Newsletter & Stay Updated
